A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
ConditionHealthy
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorMerck Sharp & Dohme LLC
About this trial
Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults.
The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.
Eligibility criteria
Qualifiers
Be in good health
Has a body mass index (BMI) between 18 and 32 kg/m², inclusive
Disqualifiers
Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m²
Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
Has a history of cancer (malignancy)
Trial design
Treatments tested in this trial
- MK-8527
- Probenecid
- Itraconazole
Treatment groups
44 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov